The MeOmics' mission is to improve the diagnosis and treatment of mental health illnesses by combining unique neuronal cell assays and data-rich descriptors of individual patients, including genomics.
This will allow preclinical screening before expensive drug trials and enable clinical screening of patients, leading to personalised mental healthcare and shortening the time and cost to better patient outcomes.
With the support of three magnificent Angel Investors and Innovate UK's Biomedical Catalyst grant funding, MeOmics has recruited, with informed consent, the biggest panel of schizophrenia patients in the world. We have demonstrated electrophysiological signals that differentiate between patient and non-patient neuronal cells. Early indications of patient stratification differences also emerge from our "brains on a chip." We are now processing the signal data by deploying AI/ML analysis techniques.
As an exciting UK startup based in South Wales, we seek pre-seed funding to progress the scale-up, collect more patient samples, increase the throughput of our unique process and technology and capture early customer revenue.
MeOmics is an exciting biotech startup operating in the health and medical sector using IP-protected stem cell technology with very high growth potential on a socially critical mission, making an exciting investment opportunity.